The FDA decision on Bausch Health Companies Inc.’s (BHC) New Drug Application for its sub-micron Loteprednol etabonate ophthalmic gel, 0.38% is expected on February 25, 2019.This product, which has a reduced concentration and reduced dosing frequency compared to existing formulations of Loteprednol etabonate, is proposed for the treatment of post-operative inflammation and pain following ocular surgery.The Company’s Loteprednol etabonate ophthalmic suspension 0.5% is approved under brand name Lotemax and is used to treat swelling and redness caused by certain eye conditions or surgery.BHC closed Tuesday’s (Jan.29, 2019) trading at $24.16, down 0.08%.